secwatch.observer — SEC 8-K summary
======================================

Issuer:     ORAMED PHARMACEUTICALS INC. (ORMP)
CIK:        0001176309
Form:       8-K
Filed at:   2025-01-03T23:59:59+00:00
Accession:  0001213900-25-000517
Event type: debt
Sentiment:  positive
Materiality: 0.65
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Oramed defers Scilex $6.25M amortization; receives 2.5M free-trading Scilex shares
--------------------------------------------------------------------------------

- Initial $6.25M amortization due Jan 2, 2025 deferred to Jan 31; further deferral to Oct 2026 conditional on royalty grant.
- Oramed receives 2.5M of 5M free-trading Scilex shares from SCLX JV as consideration for the deferral.
- Term sheet contemplates 4% royalty on global net sales of Gloperba and Elyxyb (ex-Canada) for 10 years.
- Scilex must extend $25M promissory note maturity to Dec 31, 2025; Oramed has discretion on terms.
- $1.11M cash paid to noteholders for portion of amortization and make-whole interest.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1176309/000121390025000517/0001213900-25-000517-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1176309/000121390025000517/ea0226709-8k_oramed.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-000517

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer